Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 8/20 | 0.36 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.35 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.35 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 3/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156341 | 0.93 | CYP3A4 (0.39) | TGFBR1CYP3A4CYP2C8JAK1HPGDS | |
| SCHEMBL4155882 | 0.92 | TGFBR1 (0.41) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A | |
| SCHEMBL4158310 | 0.88 | TGFBR1 (0.43) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A | |
| SCHEMBL27808359 | 0.88 | TGFBR1 (0.39) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A | |
| SCHEMBL4162033 | 0.86 | TGFBR1 (0.42) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A | |
| SCHEMBL3796138 | 0.86 | TGFBR1 (0.42) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A | |
| SCHEMBL4155020 | 0.86 | TGFBR1 (0.46) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A | |
| SCHEMBL4158052 | 0.85 | TGFBR1 (0.41) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A | |
| SCHEMBL4150529 | 0.84 | CYP3A4 (0.40) | TGFBR1CYP3A4CYP2C8JAK1HPGDS | |
| SCHEMBL4158299 | 0.83 | TGFBR1 (0.45) | TGFBR1CYP3A4CYP2C8JAK1PIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | TGFBR1 128/4885CYP3A4 111/4885CYP2C8 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.